Mizuho raised the firm’s price target on Medpace (MEDP) to $655 from $575 and keeps an Outperform rating on the shares post the Q3 report. The firm sees additional estimate upside for Medpace, saying it is not assuming a full industry recovery or additional share repurchases.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace price target raised to $485 from $425 at Barclays
- Medpace Holdings Reports Strong Q3 2025 Results
- Medpace Holdings Inc. Reports Strong Q3 2025 Growth
- Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning
- Closing Bell Movers: Tesla and IBM fall as Q3 results disappoint